Press coverage about aTyr Pharma (NASDAQ:LIFE) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the near future.
aTyr Pharma (LIFE) traded up 4.48% during trading on Friday, reaching $3.50. 49,379 shares of the company traded hands. aTyr Pharma has a 52 week low of $2.10 and a 52 week high of $4.45. The firm has a 50-day moving average price of $3.45 and a 200-day moving average price of $3.34. The company’s market capitalization is $83.32 million.
aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.06. Analysts forecast that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.
A number of research analysts recently weighed in on LIFE shares. ValuEngine upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Wednesday, July 12th. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of aTyr Pharma in a report on Wednesday, May 24th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.65.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.